Literature DB >> 11735621

Management of painful diabetic neuropathy.

P G Jensen1, J R Larson.   

Abstract

Type 2 diabetes mellitus is a prevalent disease in the US which affects more than 15 million people. As the disease progresses over time, neuropathic pain can become a common complication; it is present in more than 50% of individuals with diabetes mellitus aged >60 years. The pathogenesis of diabetic neuropathy is theorized to be multifactorial. Numerous medications, some with different mechanisms of action, have been examined regarding their effects on the symptoms associated with diabetic neuropathy such as pain, paraesthesia and numbness. However, the majority of the studies have included small patient populations. Tricyclic antidepressants, amitriptyline and desipramine in particular, have been relatively well studied and shown to be effective. However, anticholinergic adverse effects may limit their usefulness and may preclude use in the elderly. Studies have also shown gabapentin to be effective and well tolerated in the treatment of diabetic neuropathy. Capsaicin cream provides another treatment option with a favourable adverse effect profile. Many other medications have been evaluated in diabetic neuropathy; however, more placebo-controlled studies with adequate patient populations need to be performed to solidify their role in treatment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11735621     DOI: 10.2165/00002512-200118100-00003

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   4.271


  83 in total

1.  Use of levodopa to relieve pain from painful symmetrical diabetic polyneuropathy.

Authors:  M Ertas; A Sagduyu; N Arac; B Uludag; C Ertekin
Journal:  Pain       Date:  1998-04       Impact factor: 6.961

Review 2.  Explicit criteria for determining potentially inappropriate medication use by the elderly. An update.

Authors:  M H Beers
Journal:  Arch Intern Med       Date:  1997-07-28

3.  Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial.

Authors:  S H Sindrup; G Andersen; C Madsen; T Smith; K Brøsen; T S Jensen
Journal:  Pain       Date:  1999-10       Impact factor: 6.961

4.  Treatment of diabetic neuropathy with diphenylhydantoin.

Authors:  M Ellenberg
Journal:  N Y State J Med       Date:  1968-10-15

5.  Enhancement of morphine analgesia by tricyclic antidepressants.

Authors:  R T Malseed; F J Goldstein
Journal:  Neuropharmacology       Date:  1979-10       Impact factor: 5.250

6.  Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study).

Authors:  D Ziegler; M Hanefeld; K J Ruhnau; H P Meissner; M Lobisch; K Schütte; F A Gries
Journal:  Diabetologia       Date:  1995-12       Impact factor: 10.122

Review 7.  Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action.

Authors:  Søren H Sindrup; Troels S Jensen
Journal:  Pain       Date:  1999-12       Impact factor: 6.961

8.  A comparison a amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics.

Authors:  M Vrethem; J Boivie; H Arnqvist; H Holmgren; T Lindström; L H Thorell
Journal:  Clin J Pain       Date:  1997-12       Impact factor: 3.442

9.  Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.

Authors:  M Backonja; A Beydoun; K R Edwards; S L Schwartz; V Fonseca; M Hes; L LaMoreaux; E Garofalo
Journal:  JAMA       Date:  1998-12-02       Impact factor: 56.272

10.  The influence of pyridoxine in diabetic peripheral neuropathy.

Authors:  E R Levin; T A Hanscom; M Fisher; W A Lauvstad; A Lui; A Ryan; D Glockner; S R Levin
Journal:  Diabetes Care       Date:  1981 Nov-Dec       Impact factor: 19.112

View more
  9 in total

1.  Local Therapies for Localised Neuropathic Pain.

Authors:  Arun Bhaskar; Rahul Mittal
Journal:  Rev Pain       Date:  2011-06

2.  The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial.

Authors:  Lisa A Kottschade; Jeff A Sloan; Miroslaw A Mazurczak; David B Johnson; Bronagh P Murphy; Kendrith M Rowland; Deanne A Smith; Alan R Berg; Philip J Stella; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2010-10-09       Impact factor: 3.603

3.  A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA.

Authors:  Debra L Barton; Edward J Wos; Rui Qin; Bassam I Mattar; Nathan Benjamin Green; Keith S Lanier; James Dewitt Bearden; John W Kugler; Kay L Hoff; Pavan S Reddy; Kendrith M Rowland; Mike Riepl; Bradley Christensen; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2010-05-25       Impact factor: 3.603

4.  Diabetes-induced impairments of the exocytosis process and the effect of gabapentin: the link with cholesterol level in neuronal plasma membranes.

Authors:  Irene Trikash; Vitaliy Gumenyuk; Tamara Kuchmerovska
Journal:  Neurochem Res       Date:  2015-01-23       Impact factor: 3.996

5.  A cost-utility comparison of four first-line medications in painful diabetic neuropathy.

Authors:  Alec B O'Connor; Katia Noyes; Robert G Holloway
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

6.  A clinical decision support system with an integrated EMR for diagnosis of peripheral neuropathy.

Authors:  Reeda Kunhimangalam; Sujith Ovallath; Paul K Joseph
Journal:  J Med Syst       Date:  2014-04-02       Impact factor: 4.460

Review 7.  Antidepressants for chronic neuropathic pain.

Authors:  Lori Reisner
Journal:  Curr Pain Headache Rep       Date:  2003-02

8.  Duloxetine in the management of diabetic peripheral neuropathic pain.

Authors:  Michelle J Ormseth; Beth A Scholz; Chad S Boomershine
Journal:  Patient Prefer Adherence       Date:  2011-07-19       Impact factor: 2.711

9.  TRPV1: A Potential Drug Target for Treating Various Diseases.

Authors:  Rafael Brito; Sandeep Sheth; Debashree Mukherjea; Leonard P Rybak; Vickram Ramkumar
Journal:  Cells       Date:  2014-05-23       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.